by PharmacyChecker.com | Oct 3, 2011 | Drug Prices
Last week, Roger Bate, an economist and expert in counterfeit drugs with the American Enterprise Institute, wrote an article called “Google’s Ad Freedom Wrongly Curtailed.” Bate’s piece shows how banning safe foreign online pharmacies from advertising on Google and elsewhere is not only unethical but will lead to sub-optimal health outcomes. As we wrote at the end of August, the non-prosecution agreement between the U.S. Department of Justice (DOJ) and Google, in which the search engine was fined $500 million for allowing rouge Canadian sites to advertise controlled substances, is good because it forces Google to now block dangerous rogue online pharmacies from advertising. At the same time, however, it’s bad because it appears to prevent Google from allowing safe and affordable Canadian-based online pharmacies form advertising as well.
The DOJ/Google settlement appears to reflect the false rhetoric espoused by the U.S. government and pharmaceutical industry that only U.S. online pharmacies can be safe. Bate knows this is not true based on his own empirical studies, which found that properly credentialed non-U.S. online pharmacies sell genuine medication at a lower cost and require a prescription. By blocking safe Canadian pharmacies from advertising to Americans on Google, it is more difficult for needy Americans to find them. Bate writes:
Google’s current policy removes the potentially lethal sellers, but by disallowing credentialed foreign sites from advertising it will harm public health. The tens of millions of uninsured Americans who cannot afford their drugs will go online to circumvent this obstruction. If they are unaware of pharmacychecker.com’s credentialing, they will play Russian roulette and may end up buying a lethal product.
With media outlets and politicians inundated with a voracious pharmaceutical industry public relations assault that seeks to paint all non-U.S. online pharmacies as rogue, the victim here is the American seeking affordable medication online because he or she can’t afford it here at home. Bate wrote: “What is surprising is that independent groups, like Consumer Reports and AARP, have bought into this industry rhetoric or have failed to properly explain to their members that foreign doesn’t necessarily mean dangerous.” (more…)
Tagged with: AARP, adSense, advertising, AEI, American Enterprise Institute, Americans, Canada, Canadian pharmacies, Consumer Reports, controlled substances, Department of Justice, DOJ, Google, Online Pharmacies, pharmacychecker.com, Roger Bate, rogue pharmacies, safe pharmacies, United States
by Gabriel Levitt, Vice President, PharmacyChecker.com and Margaret Rode, PharmacyChecker.com | Aug 31, 2011 | Drug Prices, Healthcare Reform
A new report by the Commonwealth Fund, from their 2010 Biennial Health Insurance Survey, shows that 48 million Americans, ages 19-64, did not fill a prescription due to cost in 2010, up from 29 million in 2001 – a 66% increase. The study includes both insured and uninsured Americans but does not include children and seniors. The study indicates that the recession has greatly exacerbated the national crisis of prescription non-adherence (skipping medications), as nine out of 16 million Americans who have lost their job have also lost their health insurance.
It is difficult to estimate the sickness and even death that has resulted from so many millions of Americans not taking their prescribed medication due to cost. As evidenced by the new report, the situation is particularly dire for uninsured Americans with chronic medical conditions, as 27 million “skipped doses or did not fill a prescription for their condition because of the cost.” (more…)
Tagged with: Affordable Care Act, Biennial Health Insurance Survey, chronic, Commonwealth Fund, consumer guide, health insurance, Medicare, Medicare Drug Plans, prescription costs, skipping medicine, United States
by PharmacyChecker.com | Aug 10, 2011 | Medicare Drug Plans
Besides the obvious – access to cheap generic alternatives for once exorbitantly priced prescriptions – this year’s patent expirations on blockbuster brand-name drugs means even more good news for American consumers. A U.S. News and World Report article suggests the Patent Cliff as one of the reasons for the forecasted Medicare savings. Access to low-cost generics on popular drugs like Lipitor cuts spending significantly for plan sponsors, and U.S. officials have announced that enrollees paying for prescription drugs through Medicare Part D will not see an increase in premiums, in contrast with prior years. Rather, the yearly fees will decrease slightly – from an average of $30.76 in 2011 to $30.00 in 2012. All current plan premiums can be found on MedicareDrugPlans.com – Compare Costs and Features.
Moreover, plan enrollees are now receiving a 50% discount on brand name drugs purchased through the coverage gap. However, brand name drug prices continue to increase, which means the discount’s importance is less pronounced. (more…)
Tagged with: brand name drugs, compare costs, consumers, customer service, discount, generics, Medicare Drug Plans, Part D, Patent Cliff, U.S. News and World Report, United States
